Proteros biostructures GmbH

Proteros biostructures and Orion Pharma agree on long-term multi-target collaboration including assembly of a joint novel and unique HTS small-molecule library with full chemistry support of Enamine

Proteros receives minority investment from private equity firm Inflexion

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Proteros, co-founder of Rodin Therapeutics, announces Rodin’s acquisition by Alkermes

Proteros biostructures GmbH names Dave Lemus as new executive board member

Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets

Proteros biostructures GmbH: 23rd Conference on Protein Structure Determination in Industry (PSDI) discussing important impact of structural biology for drug discovery

Proteros signs new oncology collaboration with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA on epigenetic target

Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer

Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration

Proteros enters into a collaboration with Bayer to develop new cardiovascular drug compounds for an integral membrane protein

Update of release from 29.05.2014, 13:29 CET: Proteros announces a USD 12.9 million Series A Financing of Rodin Therapeutics

Proteros announces a USD 12 million Series A Financing of Rodin Therapeutics, a Company founded by Atlas Venture and Proteros, Focussing on Novel Treatments for CNS Disorders

Proteros biostructures GmbH: Proteros Announces Changes in Management Team

Proteros biostructures GmbH Announces Election of Prof. Eric-Paul Pâques, CEO of Grünenthal, as New Supervisory Board Member